Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of a large decrease in short interest during the month of December. As of December 13th, there was short interest totalling 3,400,000 shares, a decrease of 6.1% from the November 28th total of 3,620,000 shares. Approximately 9.9% of the shares of the stock are sold short. Based on an average trading volume of 1,000,000 shares, the days-to-cover ratio is presently 3.4 days.
In related news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 over the last quarter. Corporate insiders own 21.40% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CRSP. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in shares of Crispr Therapeutics in the 4th quarter valued at $26,000. NEXT Financial Group Inc raised its position in shares of Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE boosted its stake in shares of Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares in the last quarter. Coastal Investment Advisors Inc. acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at about $26,000. Finally, BSW Wealth Partners purchased a new position in shares of Crispr Therapeutics in the 2nd quarter valued at about $39,000. Institutional investors own 49.82% of the company’s stock.
A number of brokerages have weighed in on CRSP. Goldman Sachs Group lifted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research report on Tuesday, November 19th. Oppenheimer raised their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 30th. Roth Capital raised their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research report on Monday, December 16th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and an average target price of $71.38.
NASDAQ CRSP opened at $58.99 on Tuesday. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.31 billion, a P/E ratio of -17.15 and a beta of 3.20. Crispr Therapeutics has a 12-month low of $29.34 and a 12-month high of $74.00. The firm’s fifty day simple moving average is $65.79 and its two-hundred day simple moving average is $51.88.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, sell-side analysts predict that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.